

Setting the Standard for Healthy and Hygienic Mid-Stream Urine Sampling


The Whiz™ Mid-Stream Device has revolutionised female mid-stream urine (MSU) collection and is the only device currently on the market capable of automatically collecting a continuous and clean-catch MSU sample that is completely user independent.

The device was invented to overcome many of the problems associated with female urine collection namely:



- High contamination rates (25-30%) - false positives identification and sensitivity testing as a result of contamination
- Re-testing because of contamination
- Inaccurate/inconclusive diagnosis because of contamination
- Unnecessary prescription of antibiotics and consequently increased levels of antibiotic-resistant bacteria
- Patient discomfort and lack of hygiene (eg, spillage; urination on hands; need to stop, start and aim correctly)
- Infection control problems for patients and clinical staff
- The quality of the MSU sample collected is heavily patient dependent and the procedure requires time-consuming explanation from clinical staff
- Sample variability

The Whiz Mid-Stream Device, invented in the UK by Orde Levinson, is based on the



The amount of contaminants cultured from the MSU sample collected by the Whiz is greatly reduced compared to the growth shown in the waste urine sampled from the overflow

flow rate principle and has been designed to collect only urine that flows at more than 6ml per second. It diverts the initial flow away from the collection bottle and only once sufficient flow is established does the device capture the MSU sample. This is done automatically and is completely independent of user interference. The user therefore simply needs to urinate normally (no need to stop, start or aim) - the Whiz Mid-Stream Device does the rest! Furthermore the device has been designed in such a way that the sample bottle has an automatic maximum level of collection and stops collecting when a certain level has been reached. This essentially eliminates the possibility of spillage, making for a more hygienic method of collection.

The real ability of the Whiz Mid-Stream Device to overcome the abovementioned problems associated with conventional MSU collection methods is, nevertheless, evidenced in the results of the clinical trials (involving over 2800 patients) that were conducted in the UK. The clinical trial report will be published in the *British Journal of Urology* shortly. In brief the results of the trial were as follows:




- Reduction in general contamination - 31.44%
- Reduction in heavy mixed growth - 59.62% (this is the area largely responsible for giving false positives)
- Reduction in retest rates - 28.25%
- Improved detection of urinary tract infections (UTIs) by 9%
- Significant reduction in spillage thereby providing hygienic and infection control benefits
- Preferred to conventional techniques by a substantial majority of patients

In addition to its proven clinical effectiveness, the device also provides benefits to parties across the spectrum within the healthcare industry, such as:

Financial Benefits to the Medical Schemes or the Government due to:

- Significant reduction in the number of re-tests.
- Significant enhancement of quality of the urine sample, improving accuracy of diagnosis
- Significant reduction in number of false positives (heavy mixed growth reduced by 60%)
- Reduced possibility of unnecessary prescription of antibiotics
- Improved ability to detect infection
- Reduced unnecessary hospitalisation or an extended stay in hospital caused by an inaccurate or inconclusive result (ie, contaminated/poor quality sample)



- Infection control benefits and any cost savings related thereto

The fact that the device has recently been accepted for use in the National Health Service in the UK (which is extremely conservative) is a clear indication that the benefits and clinical effectiveness of the device outweigh its cost.

Patient benefits

- Preferred to conventional methods by a substantial majority of patients

- Samples can easily be produced by patients at home, reducing time commitment to clinical staff

General benefits

- Standardises MSU samples for the first time in medical history
- Allows for greater comparison between MSU samples
- Sets the gold standard for urine collection
- Represents best medical practice

The device complies with all regulatory issues and is CE marked in Europe, has FDA approval in the USA and Canada, and has a NAPPI code in SA. The device is currently being introduced into the local market with the support of some of the country's largest and most influential medical schemes, including Discovery Health. Furthermore, given the clinical effectiveness of the Whiz Mid-Stream Device, microbiologists around the world believe that its use should extend to the collection of most female urine samples. "Use of the device represents best medical practice and the significant benefits resulting therefrom cannot be ignored," says Dr Norman Miller, head of microbiology, National Pathology Group.

RevoMed is the exclusive southern African licensee for the Whiz Mid-Stream Device.

Contact details

RevoMed

Telephone: 012-335-3606

Fax: 012-335-7289

Cell: 082-579-5118 (Michelle Sinovich)

Email: info@revomed.com

Website: www.revomed.com

Available from RevoMed or your local wholesaler. Contact RevoMed for a supplier in your area. The Whiz Mid-Stream device is protected by worldwide design and patent rights.

Some user comments

"No uncomfortable pauses or wet hands."

"Clean and simple."

"Easy... very practical."

"Not weeing on hands and down bottle."

"Why don't doctors surgeries use these?"

"No mess, no spillages, no stop and start."

Doctors' comments

"My patients benefited from using the Whiz - it was easier to use than our current methods and for the staff it was an effective way of saving time."

Beverly White - outpatients manager, Woman's Centre, John Radcliffe Hospital, Oxford, UK.

"The Whiz is highly attractive to clinician and patient alike; it significantly lowered contamination rates and hence the need to repeat urinalysis. My patients were pleased to use this simple and hygienic device."

Dr Simon Jackson - head of obstetrics and gynaecology, John Radcliffe Hospital, Oxford, UK.